基于网络药理学的研究,针对非胰岛素依赖糖尿病的TCM配方
Avani Jha1, Shashi Kumar Sampangin Venkatesh1, Naga Rajiv Lakkaniga1
1Department of Chemistry and Chemical Biology, Indian Institute of Technology (Indian School of Mines), Dhanbad, Jharkhand India.
In silico pharmacology
|November 3, 2025
概括
网络药理学在非胰岛素依赖性糖尿病 (NIDDM) 中确定了HuaJiao的133个基因标. 分子动力学证实了像哈普洛宾这样的化合物的稳定结合,这表明了传统中医 (TCM) 疗法的潜力.
科学领域:
- 药理学 药理学是指药理学的学科.
- 计算生物学 计算生物学
- 传统中国医药 传统中国医药
背景情况:
- 传统中医 (TCM) 使用多组分疗法来治疗诸如非胰岛素依赖糖尿病 (NIDDM) 等复杂疾病.
- 华是用于NIDDM的几个TCM配方中的一种成分.
- 了解TCM的分子机制对于开发有效治疗方法至关重要.
研究的目的:
- 用网络药理学阐明在NIDDM中含有华的TCM配方的化合物-基因相互作用.
- 在这些配方中识别关键的分子标和生物活性化合物.
- 通过分子对接和动态模拟来验证已识别的化合物的治疗潜力.
主要方法:
- 网络药理学方法利用像ETCM 2.0和TCMSP这样的数据库.
- 与CTD,TTD和ETCM的NIDDM相关基因交叉引用生物活性化合物和标.
- 使用Cytoscape构建和可视化一个复合目标网络.
- 分子对接和200-ns分子动力学模拟用于验证.
主要成果:
- 在五种含有华的TCM配方中确定了133个常见的基因标.
- 突出显示了参与胰岛素信号传递,葡萄糖平衡和炎症的枢纽基因.
- 证实了斯巴图伦醇和哈普洛宾对相关标的稳定结合,包括哈普洛宾的COX-2.
结论:
- 与分子动力学集成的网络药理学为NIDDM提供了对TCM的机制性见解.
- 华化合物,特别是斯巴图伦醇和哈普洛宾,表现出多药性潜力.
- 这些发现支持基于TCM的新型干预措施的合理设计,用于非胰岛素依赖的糖尿病.
更多相关视频
12:34Author Spotlight: Exploring ShiDuGao's Multi-Target Approach in Anus Eczema Treatment
Published on: January 12, 2024
1.2K
13:18Network Pharmacology Prediction and Experimental Validation of Trichosanthes-Fritillaria thunbergii Action Mechanism Against Lung Adenocarcinoma
Published on: March 3, 2023
1.7K
相关概念视频
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
571
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
571
01:27Insulin Formulations: Types and Delivery
638
Insulin preparations are categorized by their duration of action into short-acting and long-acting types. Two strategies are used to modify insulin's absorption and pharmacokinetic profile: slowing the absorption post-subcutaneous injection, or altering human insulin's amino acid sequence or protein structure. These changes retain the insulin's ability to bind to the insulin receptor, but alter its behavior in solution or after injection.
Short-acting insulins are divided into...
Short-acting insulins are divided into...
638